former chief business officer · Aldeyra Therapeutics, Inc. (ALDX)

David McMullin

A named executive officer of Aldeyra Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,963,836

Salary $395,000Stock awards $935,474

FY2018: $1,584,445

2nd of 3 named executive officers at Aldeyra Therapeutics by FY2020 total.

3 named officers on file for Aldeyra Therapeutics, FY2020

David McMullin’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aldeyra Therapeutics’s whole pay program stands against its peers

  • Aldeyra Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ALDX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 14, 2021 (DEF 14A).

Free

Get David McMullin’s full pay file as a PDF — free

More than this page: up to 10 years of David’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

David McMullin compensation by year

Aldeyra Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Aldeyra Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2020
Salary$234,932$395,000
Bonus$0$0
Stock awards$0$935,474
Option awards$1,279,034$621,962
Non-equity incentive$70,479$0
Pension and deferred compensation$0$0
All other$0$11,400
Total$1,584,445$1,963,836

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aldeyra Therapeutics, Inc. DEF 14A filed April 14, 2021, accession 0001564590-21-018847, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aldeyra Therapeutics, Inc. filed document, accession 0001564590-21-018847. Every figure is read from that document and cited to the page and table it appears in. Filed April 14, 2021.

$1.6M
$2.0M
FY18
FY20
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU247,480$1,697,713—
Option192,709—$3.78
Option79,697—$8.10
Option23,549—$8.05

Per the Outstanding Equity Awards at Fiscal Year-End table in Aldeyra Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Aldeyra Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Todd BradyPresident and Chief Executive Officer$2,421,362
David McMullin · this pageformer chief business officer$1,963,836
Joshua ReedChief Financial Officer$1,688,894

The full Aldeyra Therapeutics compensation record

free company brief

This page is one person within Aldeyra Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aldeyra Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David McMullin's compensation dossier · One-time report. No refunds.